F
Francesco De Blasio
Researcher at University of Molise
Publications - 34
Citations - 642
Francesco De Blasio is an academic researcher from University of Molise. The author has contributed to research in topics: COPD & Bioelectrical impedance analysis. The author has an hindex of 12, co-authored 30 publications receiving 478 citations. Previous affiliations of Francesco De Blasio include University of Naples Federico II.
Papers
More filters
Journal ArticleDOI
Anatomy and neuro-pathophysiology of the cough reflex arc
Mario Polverino,Francesca Polverino,Marco Fasolino,Filippo Andò,Antonio Alfieri,Francesco De Blasio +5 more
TL;DR: The anatomy and the neuro-pathophysiology of the cough reflex arc are analyzed and the anatomic and pathophysiologic elements of evaluation of the complex and multiple etiologies of cough are provided.
Journal ArticleDOI
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.
Corrado Pelaia,Cecilia Calabrese,Rosa Terracciano,Francesco De Blasio,Alessandro Vatrella,Girolamo Pelaia +5 more
TL;DR: Omalizumab effectively blunts the immune response in atopic asthmatic patients, thus significantly improving the control of asthma symptoms and successfully preventing disease exacerbations.
Journal ArticleDOI
Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables
Francesca de Blasio,Ada Di Gregorio,Francesco De Blasio,Andrea Bianco,Barbara Bellofiore,Luca Scalfi +5 more
TL;DR: A relatively high prevalence of malnutrition and sarcopenia was found in COPD patients applying international standard criteria, with some discrepancy between the two diagnoses.
Journal ArticleDOI
Cough management: a practical approach
Francesco De Blasio,Johann Christian Virchow,Mario Polverino,Alessandro Zanasi,Panagiotis Behrakis,Gunsely Kilinç,Rossella Balsamo,Gianluca De Danieli,Luigi Lanata +8 more
TL;DR: Among drugs used for the symptomatic treatment of cough, peripherally acting anti-tussives such as levodropropizine and moguisteine show the highest level of benefit and should be recommended especially in children.
Journal ArticleDOI
An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome
Francesco De Blasio,Peter V. Dicpinigaitis,Bruce K. Rubin,Gianluca De Danieli,Luigi Lanata,Alessando Zanasi +5 more
TL;DR: In children treated with cough suppressants, the duration, type, intensity, and frequency cough were similar at baseline in the two groups respectively treated with levodropropizine and central antitussives (cloperastine and codeine).